the sun malaysia ipaper logo 150x150
Friday, July 3, 2026
27.5 C
Kuala Lumpur
the sun malaysia ipaper logo 150x150

Toyota, Mazda halt production of 5 models over certification test fraud

TOKYO: Japanese auto giants Toyota and Mazda suspended production of five car models on Thursday due to fraudulent practices discovered in national certification tests, in the wake of a cheating scandal among five major Japanese automakers, reported Xinhua.

Following the order of the Japanese Transport Ministry to halt shipments of affected models, Toyota Motor Corporation halted production of three models, including the Yaris Cross, at its factories in the prefectures of Miyagi and Iwate, with the suspension expected to last until June 28.

Meanwhile, Mazda Motors Corporation, ceased its production of two models, including MAZDA2, at its factories in the prefectures of Hiroshima and Yamaguchi.

The suspension came after the Ministry of Land, Infrastructure, Transport and Tourism disclosed that Toyota, Honda Motor, Mazda, Yamaha Motor and Suzuki Motor have been implicated in illegal fraudulent practices during their mass production certification applications.

With a substantial combined impact on both companies’ supply chains, the disruption is causing significant concern for regional economies, particularly for small- and medium-sized enterprises that are integral to the supply network, according to local media reports.

It is estimated that the production halts are affecting over 1,000 suppliers for Toyota and about 300 for Mazda.

Emphasising efforts to mitigate the economic repercussions, Chief Cabinet Secretary Yoshimasa Hayashi said the Transport Ministry would expedite compliance verification tests to minimise the economic impact of the halted shipments.

Neither Toyota nor Mazda has specified when production will resume for the affected models.

STAY AHEAD OF THE CURVE

Join our community for instant updates and exclusive content.

Join Telegram Channel

Related


spot_img

Latest News

Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations

TAIPEI, TAIWAN - Media OutReach Newswire - 2 July 2026 - Bora Pharmaceuticals Co., Ltd. ("Bora" or "Bora Group"; TWSE: 6472; OTCQX: BORAY) today announced the completion of its acquisition of the GMP manufacturing operations of MacroGenics, Inc. (NASDAQ: MGNX) including its biologics drug substance facility in Rockville, Maryland and an associated warehousing center in Frederick, Maryland, for total consideration of US $122.5 million through its wholly owned subsidiary Bora Biologics USA, LLC.. Upon closing, Bora signed a long-term CDMO Service Agreement with MacroGenics.

Most Viewed

spot_img
WC26

World Cup 2026

Updates, Fixtures, Results & Standings